nach oben

Current Breast Cancer Reports

Erschienen in:

19.07.2019 | Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?

verfasst von: Jennifer K. Plichta, Laura H. Rosenberger, Cosette A. DeChant, E. Shelley Hwang

Erschienen in: Current Breast Cancer Reports | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Standard treatment for ductal carcinoma in situ (DCIS) is similar to that of invasive carcinoma. However, there is significant controversy regarding the true clinical implications of DCIS, and thus, the best management strategy. The aim of this review is to highlight relevant biology, diagnostic considerations, treatment options, and recent clinical trials.

Recent Findings

Outcomes are generally excellent with low recurrence rates and exceptional disease-specific survival. Outcomes can be predicted using various prognostic indicators and/or nomograms to guide treatment decisions. Ongoing clinical trials of active surveillance are based upon the argument that ipsilateral invasive recurrence is the most clinically meaningful endpoint. These trials seek to compare ipsilateral invasive cancer diagnoses between standard of care and close monitoring.

Summary

Recent trials have revealed the marked heterogeneity in the biology of DCIS, offering an opportunity to de-escalate therapy for women at lowest risk for progression. DCIS also presents an ideal setting in which to test novel prevention agents. Future care of patients with DCIS will include biomarker-based risk assessment in order to better individualize treatment to biologic risk of invasive progression.

How Common Is Breast Cancer? American Cancer Society. 2018. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html. Accessed 5/16/2018.

Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139–41. https://doi.org/10.1093/jncimonographs/lgq027.CrossRefPubMedPubMedCentral

Allison KH, Abraham LA, Weaver DL, Tosteson AN, Nelson HD, Onega T, et al. Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the breast Cancer surveillance consortium. Cancer. 2015;121(9):1369–78. https://doi.org/10.1002/cncr.29199.CrossRefPubMedPubMedCentral

Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–8. https://doi.org/10.1093/jnci/djp482.CrossRefPubMed

Bruening W, Fontanarosa J, Tipton K, Treadwell JR, Launders J, Schoelles K. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med. 2010;152(4):238–46. https://doi.org/10.7326/0003-4819-152-1-201001050-00190.CrossRefPubMed

Darling ML, Smith DN, Lester SC, Kaelin C, Selland DL, Denison CM, et al. Atypical ductal hyperplasia and ductal carcinoma in situ as revealed by large-core needle breast biopsy: results of surgical excision. AJRAm J Roentgenol. 2000;175(5):1341–6.CrossRef

Mittendorf EA, Arciero CA, Gutchell V, Hooke J, Shriver CD. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy. Curr Surg. 2005;62(2):253–7. https://doi.org/10.1016/j.cursur.2004.09.011.CrossRefPubMed

Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr. 2010;2010(41):134–8. https://doi.org/10.1093/jncimonographs/lgq035.CrossRefPubMedPubMedCentral

Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15–25. https://doi.org/10.1043/1543-2165-133.1.15.CrossRefPubMed

10.

Lester SC, Bose S, Chen YY, Connolly JL, De Baca ME, Fitzgibbons PL et al. Protocol for the Examination of Specimens From Patients With Ductal Carcinoma In Situ (DCIS) of the Breast College of American Pathologists. 2013. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-breast-dcis-13protocol-3200.pdf&_ga=2.86995600.981279591.1538851930-1326061859.1538851930. Accessed 10/5/2018.

11.

Cancer Staging Manual AJCC. 8th ed. New York, NY: Springer International Publishing; 2016.

12.

Kempson RL. Surgical Pathology Criteria: DCIS. 2006. http://surgpathcriteria.stanford.edu/breast/dcis/. Accessed 10/5/2018.

13.

Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. Jama. 2015;313(11):1122–32. https://doi.org/10.1001/jama.2015.1405.CrossRefPubMedPubMedCentral

14.

Jackson SL, Frederick PD, Pepe MS, Nelson HD, Weaver DL, Allison KH, et al. Diagnostic reproducibility: what happens when the same pathologist interprets the same breast biopsy specimen at two points in time? Ann Surg Oncol. 2017;24(5):1234–41. https://doi.org/10.1245/s10434-016-5695-0.CrossRefPubMed

15.

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Janicke F, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2010;123(3):757–65. https://doi.org/10.1007/s10549-009-0675-8.CrossRefPubMed

16.

Buerger H, Otterbach F, Simon R, Schafer KL, Poremba C, Diallo R, et al. Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 1999;189(4):521–6. https://doi.org/10.1002/(sici)1096-9896(199912)189:4<521::Aid-path472>3.0.Co;2-b.CrossRefPubMed

17.

Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10(15):5160–7. https://doi.org/10.1158/1078-0432.Ccr-04-0165.CrossRefPubMed

18.

Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res. 2015;75(18):3980–90. https://doi.org/10.1158/0008-5472.Can-15-0506.CrossRefPubMedPubMedCentral

19.

Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, et al. Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res. 2016;18(1):22. https://doi.org/10.1186/s13058-016-0675-7.CrossRefPubMedPubMedCentral

20.

Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA. 2005;293(8):964–9. https://doi.org/10.1001/jama.293.8.964.CrossRefPubMed

21.

Reeves GK, Pirie K, Green J, Bull D, Beral V. Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. 2012;131(4):930–7. https://doi.org/10.1002/ijc.26460.CrossRefPubMed

22.

Sanders ME, Schuyler PA, Simpson JF, Page DL, Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up. Mod Pathol. 2015;28(5):662–9. https://doi.org/10.1038/modpathol.2014.141.CrossRefPubMed

23.

Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–44. https://doi.org/10.1007/s10549-005-9101-z.CrossRefPubMed

24.

Khan S, Epstein M, Lagios MD, Silverstein MJ. Are we Overtreating ductal carcinoma in situ (DCIS)? Ann Surg Oncol. 2017;24(1):59–63. https://doi.org/10.1245/s10434-016-5501-z.CrossRefPubMed

25.

Barreau B, de Mascarel I, Feuga C, MacGrogan G, Dilhuydy MH, Picot V, et al. Mammography of ductal carcinoma in situ of the breast: review of 909 cases with radiographic-pathologic correlations. Eur J Radiol. 2005;54(1):55–61. https://doi.org/10.1016/j.ejrad.2004.11.019.CrossRefPubMed

26.

Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast Cancer. Radiology. 2004;233(3):830–49. https://doi.org/10.1148/radiol.2333031484.CrossRefPubMed

27.

Greenwood HI, Heller SL, Kim S, Sigmund EE, Shaylor SD, Moy L. Ductal carcinoma in situ of the breasts: review of MR imaging features. Radiographics. 2013;33(6):1569–88. https://doi.org/10.1148/rg.336125055.CrossRefPubMed

28.

Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007;370(9586):485–92. https://doi.org/10.1016/s0140-6736(07)61232-x.CrossRefPubMed

29.

Badan GM, Piato S, Roveda DJ. de Faria Castro Fleury E. predictive values of BI-RADS((R)) magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS). Eur J Radiol. 2016;85(10):1701–7. https://doi.org/10.1016/j.ejrad.2016.07.010.CrossRefPubMed

30.

• Preibsch H, Beckmann J, Pawlowski J, Kloth C, Hahn M, Staebler A, et al. Accuracy of breast magnetic resonance imaging compared to mammography in the preoperative detection and measurement of pure ductal carcinoma in situ: a retrospective analysis. Acad Radiol. 2018. https://doi.org/10.1016/j.acra.2018.07.013. This study reviews the accuracy of breast MRI and mammography for women diagnosed with DCIS. It demonstrated that MRI may outperform mammography in detecting and estimating size of DCIS.

31.

Aminololama-Shakeri S, Flowers CI, McLaren CE, Wisner DJ, de Guzman J, Campbell JE, et al. Can radiologists predict the presence of ductal carcinoma in situ and invasive breast Cancer? AJR Am J Roentgenol. 2017;208(4):933–9. https://doi.org/10.2214/ajr.16.16073.CrossRefPubMed

32.

Strobel K, Schrading S, Hansen NL, Barabasch A, Kuhl CK. Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging. Radiology. 2015;274(2):343–51. https://doi.org/10.1148/radiol.14140645.CrossRefPubMed

33.

Izumori A, Takebe K, Sato A. Ultrasound findings and histological features of ductal carcinoma in situ detected by ultrasound examination alone. Breast Cancer. 2010;17(2):136–41. https://doi.org/10.1007/s12282-009-0134-8.CrossRefPubMed

34.

Bent CK, Bassett LW, D'Orsi CJ, Sayre JW. The positive predictive value of BI-RADS microcalcification descriptors and final assessment categories. AJR Am J Roentgenol. 2010;194(5):1378–83. https://doi.org/10.2214/ajr.09.3423.CrossRefPubMed

35.

Lehman CD. Magnetic resonance imaging in the evaluation of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):150–1. https://doi.org/10.1093/jncimonographs/lgq030.CrossRefPubMedPubMedCentral

36.

Petrillo A, Fusco R, Petrillo M, Triunfo F, Filice S, Vallone P, et al. Added value of breast MRI for preoperative diagnosis of ductal carcinoma in situ: diagnostic performance on 362 patients. Clin Breast Cancer. 2017;17(3):e127–e34. https://doi.org/10.1016/j.clbc.2016.12.007.CrossRefPubMed

37.

Allen LR, Lago-Toro CE, Hughes JH, Careaga E, Brown AT, Chernick M, et al. Is there a role for MRI in the preoperative assessment of patients with DCIS? Ann Surg Oncol. 2010;17(9):2395–400. https://doi.org/10.1245/s10434-010-1000-9.CrossRefPubMed

38.

Davis KL, Barth RJ Jr, Gui J, Dann E, Eisenberg B, Rosenkranz K. Use of MRI in preoperative planning for women with newly diagnosed DCIS: risk or benefit? Ann Surg Oncol. 2012;19(10):3270–4. https://doi.org/10.1245/s10434-012-2548-3.CrossRefPubMed

39.

•• Gradishar WJ, Anderson BO, Aft R, Balassanian R, Blair SL, Burstein HJ et al. NCCN guidelines: breast Cancer, version 1.20182018 3/20/2018. Review of the standard guidelines for diagnosing and treating DCIS.

40.

Pilewskie M, Olcese C, Eaton A, Patil S, Morris E, Morrow M, et al. Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol. 2014;21(5):1552–60. https://doi.org/10.1245/s10434-013-3424-5.CrossRefPubMedPubMedCentral

41.

Waddell BE, Stomper PC, DeFazio JL, Hurd TC, Edge SB. Postexcision mammography is indicated after resection of ductal carcinoma-in-situ of the breast. Ann Surg Oncol. 2000;7(9):665–8.CrossRefPubMed

42.

ASTRO. ASTRO Choosing Wisely: Don't routinely recommend follow-up mammograms more often than annually for women who have had radiotherapy following breast conserving surgery. Online: http://www.choosingwisely.org/clinician-lists/american-society-radiation-oncology-follow-up-mammograms-following-radiotherapy-for-breast-conservation/2014. Accessed 11/5/2018.

43.

Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260(1):119–28. https://doi.org/10.1148/radiol.11102368.CrossRefPubMed

44.

• Pilewskie M, Olcese C, Patil S, Van Zee KJ. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy? Ann Surg Oncol. 2016;23(13):4253–61. https://doi.org/10.1245/s10434-016-5595-3. The 10-year invasive-IBTR rates for Among women meeting LORIS criteria undergoing excision without RT, the 10-year invasive-IBTR rate was 6%. Roughly 20% of women with core biopsy-proven non-high-grade DCIS had invasive cancer at excision.

45.

•• Grimm LJ, Ryser MD, Partridge AH, Thompson AM, Thomas JS, Wesseling J, et al. Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. Ann Surg Oncol. 2017;24(12):3534–40. https://doi.org/10.1245/s10434-017-6018-9. DCIS upstaging rates in women eligible for active surveillance trials are low (6–10%). With careful patient selection, active surveillance trials for DCIS have a low risk of missing occult invasive cancer.

46.

Soumian S, Verghese ET, Booth M, Sharma N, Chaudhri S, Bradley S, et al. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed low risk DCIS trial (LORIS). Eur J Surg Oncol. 2013;39(12):1337–40. https://doi.org/10.1016/j.ejso.2013.09.028.CrossRefPubMed

47.

Francis A, Fallowfield L, Rea D. The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ. Clin Oncol (Royal College of Radiologists (Great Britain)). 2015;27(1):6–8. https://doi.org/10.1016/j.clon.2014.09.015.CrossRef

48.

Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study. Eur J Cancer. 2015;51(12):1497–510. https://doi.org/10.1016/j.ejca.2015.05.008.CrossRefPubMed

49.

• Lynch T, Frank ES, Collyar DE, Basila D, Pinto D, Partridge A, et al. Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study). J Clin Oncol. 2018;36(15_suppl):TPS599-TPS. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS599. This is an example of one of the ongoing clinical trials evaluating active surveillance for low risk DCIS.

50.

Mercieca-Bebber R, King MT, Boxer MM, Spillane A, Winters ZE, Butow PN, et al. What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions? Breast Cancer. 2017;24(5):720–9. https://doi.org/10.1007/s12282-017-0765-0.CrossRefPubMed

51.

Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast. 2009;18(3):143–9. https://doi.org/10.1016/j.breast.2009.04.003.CrossRefPubMed

52.

Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, et al. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study. J Clin Oncol. 2016;34(11):1190–6. https://doi.org/10.1200/JCO.2015.65.1869.CrossRefPubMedPubMedCentral

53.

Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A, Chen P, et al. Association of Radiotherapy Boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol. 2017;3(8):1060–8. https://doi.org/10.1001/jamaoncol.2016.6948.CrossRefPubMedPubMedCentral

54.

Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med. 1999;340(19):1455–61. https://doi.org/10.1056/NEJM199905133401902.CrossRefPubMed

55.

McCahill LE, Single RM, Aiello Bowles EJ, Feigelson HS, James TA, Barney T, et al. Variability in reexcision following breast conservation surgery. JAMA. 2012;307(5):467–75. https://doi.org/10.1001/jama.2012.43.CrossRefPubMed

56.

Morrow M, Jagsi R, Alderman AK, Griggs JJ, Hawley ST, Hamilton AS, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302(14):1551–6. https://doi.org/10.1001/jama.2009.1450.CrossRefPubMedPubMedCentral

57.

• Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Ann Surg Oncol. 2016;23(12):3801–10. https://doi.org/10.1245/s10434-016-5449-z. This study established that excision of DCIS requires a negative margin width of 2 mm.

58.

Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Annals of surgical oncology. 2014;21(3):704–16. https://doi.org/10.1245/s10434-014-3481-4.CrossRefPubMed

59.

• van Roozendaal LM, Goorts B, Klinkert M, Keymeulen K, De Vries B, Strobbe LJA, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat. 2016;156(3):517–25. https://doi.org/10.1007/s10549-016-3783-2. The incidence of significant lymph node metastasis in women with DCIS is extremely low, and thus, sentinel lymph node biopsy is not recommended for women undergoing lumpectomy.

60.

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88. https://doi.org/10.1093/jnci/djr027.CrossRefPubMedPubMedCentral

61.

Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol. 2013;31(32):4054–9. https://doi.org/10.1200/JCO.2013.49.5077.CrossRefPubMed

62.

Warnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol. 2014;32(32):3613–8. https://doi.org/10.1200/JCO.2014.56.2595.CrossRefPubMed

63.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21–9. https://doi.org/10.1016/S1470-2045(10)70266-7.CrossRefPubMed

64.

Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, Nofech-Mozes S, Hanna W, et al. Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2014;90(5):1017–24. https://doi.org/10.1016/j.ijrobp.2014.07.026.CrossRefPubMed

65.

Nilsson C, Valachis A. The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol. 2015;114(1):50–5. https://doi.org/10.1016/j.radonc.2015.01.001.CrossRefPubMed

66.

Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013;20(13):4103–12. https://doi.org/10.1245/s10434-013-3194-0.CrossRefPubMedPubMedCentral

67.

Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, et al. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? Int J Radiat Oncol Biol Phys. 2011;80(1):25–30. https://doi.org/10.1016/j.ijrobp.2010.01.044.CrossRefPubMed

68.

Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and bowel project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000. https://doi.org/10.1016/S0140-6736(99)05036-9.CrossRefPubMed

69.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387(10021):866–73. https://doi.org/10.1016/S0140-6736(15)01129-0.CrossRefPubMedPubMedCentral

70.

• Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2016;387(10021):849–56. https://doi.org/10.1016/S0140-6736(15)01168-X. This randomized trial demonstrated the improved outcomes with anastrozole compared to tamoxifen in post-menopausal women, similar to that observed in those with invasive carcinoma.

71.

Kerlikowske K, Molinaro A, Cha I, Ljung BM, Ernster VL, Stewart K, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692–702.CrossRefPubMed

72.

Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 1999;85(3):616–28.CrossRefPubMed

73.

Arvold ND, Punglia RS, Hughes ME, Jiang W, Edge SB, Javid SH, et al. Pathologic characteristics of second breast cancers after breast conservation for ductal carcinoma in situ. Cancer. 2012;118(24):6022–30. https://doi.org/10.1002/cncr.27691.CrossRefPubMedPubMedCentral

74.

Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, et al. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J Natl Cancer Inst. 2015;107(12):djv263. https://doi.org/10.1093/jnci/djv263.CrossRefPubMedPubMedCentral

75.

Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995;345(8958):1154–7.CrossRefPubMed

76.

Silverstein MJ, Lagios MD. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J. 2015;21(2):127–32. https://doi.org/10.1111/tbj.12368.CrossRefPubMed

77.

Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9. https://doi.org/10.1200/jco.2009.26.8847.CrossRefPubMed

78.

Breast Cancer Nomogram: Ductal Carcinoma In Situ (DCIS) Recurrence. Memorial Sloan Kettering Cancer Center. http://nomograms.mskcc.org/breast/DuctalCarcinomaInSituRecurrencePage.aspx. Accessed 10/6/2018.

79.

Wang F, Li H, Tan PH, Chua ET, Yeo RM, Lim FL, et al. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for Asian women with ductal carcinoma in situ of the breast. Clin Oncol (R Coll Radiol (Great Britain)). 2014;26(11):684–91. https://doi.org/10.1016/j.clon.2014.08.004.CrossRef

80.

Collins LC, Achacoso N, Haque R, Nekhlyudov L, Quesenberry CP Jr, Schnitt SJ, et al. Risk prediction for local breast Cancer recurrence among women with DCIS treated in a community practice: a nested, case-control study. Ann Surg Oncol. 2015;22(Suppl 3):S502–8. https://doi.org/10.1245/s10434-015-4641-x.CrossRefPubMed

81.

Sweldens C, Peeters S, van Limbergen E, Janssen H, Laenen A, Patil S, et al. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer J (Sudbury, Mass). 2014;20(1):1–7. https://doi.org/10.1097/ppo.0000000000000025.CrossRef

82.

Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2008;111(3):531–40. https://doi.org/10.1007/s10549-007-9807-1.CrossRefPubMed

83.

Stout NK, Cronin AM, Uno H, Ozanne EM, Hassett MJ, Frank ES, et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Res Treat. 2018;171(3):777–81. https://doi.org/10.1007/s10549-018-4860-5.CrossRefPubMed

84.

Molinaro AM, Sison JD, Ljung BM, Tlsty TD, Kerlikowske K. Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy. Breast Cancer Res Treat. 2016;157(2):351–61. https://doi.org/10.1007/s10549-016-3814-z.CrossRefPubMedPubMedCentral

85.

•• Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015;1(7):888–96. https://doi.org/10.1001/jamaoncol.2015.2510. Based upon SEER data, the breast cancer-specific mortality at 20 years for women with DCIS was 3.3%. Radiotherapy did not diminish breast cancer mortality at 10 years. After a diagnosis of an ipsilateral invasive breast cancer, the risk of death increased.

86.

Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10. https://doi.org/10.1093/jnci/djt067.CrossRefPubMedPubMedCentral

87.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol. 2015;33(33):3938–44. https://doi.org/10.1200/jco.2015.60.8588.CrossRefPubMedPubMedCentral

88.

• Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, et al. Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat. 2018;169(2):359–69. https://doi.org/10.1007/s10549-018-4693-2. The Oncotype DX DCIS Score, age at diagnosis, tumor size, and year of diagnosis were shown to provide independent prognostic information on the risk of local recurrence.

89.

• Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, et al. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. Clin Cancer Res. 2018;24(23):5895–901. https://doi.org/10.1158/1078-0432.Ccr-18-0842. This study demonstrates that a biological signature (an individualized Decision Score) was prognostic for risk and predicted RT benefit for DCIS patients.

90.

McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709–15. https://doi.org/10.1200/jco.2014.57.9029.CrossRefPubMedPubMedCentral

91.

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer. N Engl J Med. 2016;375(15):1415–24. https://doi.org/10.1056/NEJMoa1606220.CrossRefPubMed

92.

Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51(16):2296–303. https://doi.org/10.1016/j.ejca.2015.07.017.CrossRefPubMed

93.

Hwang ES, Hyslop T, Lynch T, Frank ES, Pinto D, Basila D, et al. The COMET (comparison of operative to monitoring and endocrine therapy) trial: a phase III randomized trial for low-risk ductal carcinoma in situ (DCIS). BMJ. 2019;12; 9(3):e026797.

94.

•• ClinicalTrials.gov. National Library of Medicine (NLM) at the National Institutes of Health (NIH). 2019. https://clinicaltrials.gov/. Accessed 1/15/2019 2019. Online resource with summaries of the most recent and ongoing clinical trials related to DCIS.

Titel: Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?
verfasst von: Jennifer K. Plichta
Laura H. Rosenberger
Cosette A. DeChant
E. Shelley Hwang
Publikationsdatum: 19.07.2019
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports / Ausgabe 3/2019
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-019-0306-2

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and Kenya

Mammographic Density: Intersection of Advocacy, Science, and Clinical Practice

Breast Atypia as a Biomarker of Risk

Breast Cancer Management Among Refugees and Forcibly Displaced Populations: a Call to Action

Polygenic Risk Scores in Breast Cancer

Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie